Tumor-specific T cell responses against multiple antigens overexpressed by OC, including folate receptor alpha (FRα), New York Esophageal Squamous Cell Carcinoma 1 (NY-ESO-1), p53, human epidermal growth factor receptor 2/neu (HER-2/neu), survivin, sperm surface protein 17 (Sp17), Wilms’ tumor 1 (WT1), transmembrane glycoprotein mucin 1 (MUC1), and melanoma-associated antigen-3 (MAGE-3), are quantifiable and highlight the potential for immunotherapy in treating OC (5–12). This evidence concerns the gene ERBB2 and neoplasm.